U.S. Online Retail and Ecommerce Stock News

NasdaqGS:CCEC
NasdaqGS:CCECShipping

Capital Clean Energy Carriers (CCEC) Enters LNG Bunkering, Is The Upside Already Priced In?

Capital Clean Energy Carriers stock reacts to new LNG bunkering joint venture Capital Clean Energy Carriers (CCEC) has drawn fresh attention after announcing a 50/50 joint venture with CMA CGM to construct, charter, and operate a 20,000 cbm dual-fuel LNG bunkering vessel. The project, priced at US$82.8 million with delivery targeted for the third quarter of 2028, is backed by an expected 12-year time charter to a CMA CGM and TotalEnergies joint venture. This highlights long-term contract...
NYSE:FLG
NYSE:FLGBanks

Interest Rates Put Lemonade Flagstar Bank And Oscar Health Stock In Focus

The passing of former Federal Reserve Chairman Alan Greenspan has pushed monetary policy back into the spotlight, with investors reassessing how interest rates, liquidity and risk appetite shape the outlook for large financial institutions. For stocks in our Financial Sector Stocks screener, this renewed focus on Fed decisions and “irrational exuberance” can influence how investors view balance sheet strength, earnings quality and valuation. This article walks through 3 stocks from that...
NasdaqGM:RUM
NasdaqGM:RUMInteractive Media and Services

Is RUM Group (RUM) Undervalued Or Is Its Growth Story Already Priced In?

RUM Group (RUM) is back in focus after recent trading left the stock at a last close of US$7.36, with returns mixed over different periods and revenue far above current net income. See our latest analysis for RUM Group. Over the past year RUM Group’s share price return has swung between shorter term weakness and stronger multi month gains, with a 90 day share price return of 43.75% contrasting with a 1 year total shareholder return that declined 10.90%. If you are weighing RUM Group against...
NasdaqGM:OLLI
NasdaqGM:OLLIMultiline Retail

Ollie's Bargain Outlet (OLLI) Stock After 31% Slide Is The Pullback Enough Now

If you are wondering whether Ollie's Bargain Outlet Holdings is starting to look attractive at its current price, this article will walk through what the recent share performance and valuation checks actually say. The stock last closed at US$76.91, with the share price down 9.5% over the past week, down 6.0% over the past month and down 30.9% year to date. The 3 year return is up 27.8%, while the 5 year return is down 10.0%. Recent coverage around Ollie's Bargain Outlet Holdings has focused...
NasdaqGM:XENE
NasdaqGM:XENEBiotechs

Is Positive X-TOLE2 Epilepsy Data And 2026 FDA Filing Plan Altering The Investment Case For Xenon Pharmaceuticals (XENE)?

Xenon Pharmaceuticals recently reported highly positive Phase III X-TOLE2 results for azetukalner in focal onset seizures and has since confirmed plans to submit a new drug application to the FDA for this indication in the third quarter of 2026. This progress strengthens the company’s neuroscience-focused pipeline by advancing azetukalner toward potential commercialization in epilepsy, a core area of its long-term growth plans. We’ll now examine how the successful X-TOLE2 trial and upcoming...
NYSE:IQV
NYSE:IQVLife Sciences

IQVIA Holdings (IQV) Stock After Mixed Returns And DCF Valuation Gap

If you are wondering whether IQVIA Holdings is attractively priced or looking stretched, this article breaks down what the current share price might imply about value. The stock last closed at US$171.28, with the share price up 2.0% over the past month but down 24.0% year to date and 29.8% over five years. The 1 year return stands at 8.0% and the 3 year return shows a 20.2% decline. Recent coverage around IQVIA Holdings has focused on its role in life sciences data and clinical services, as...
NYSE:SXT
NYSE:SXTChemicals

Sensient Technologies (SXT) Stock After Strong Multi‑Year Run Are Recent Gains Justified

If you are wondering whether Sensient Technologies stock still offers value at current levels, this article focuses squarely on what the numbers say about its price. Over recent periods, the stock has recorded returns of 6.3% over 7 days, 3.8% over 30 days, 27.1% year to date, 23.3% over 1 year, 80.8% over 3 years, and 52.4% over 5 years. This naturally raises questions about how its current valuation stacks up. Recent coverage around Sensient Technologies has focused on its role in the...
NYSE:BMNR
NYSE:BMNRSoftware

Bitmine Immersion Technologies (BMNR) Nears Russell 1000 Entry And Co Founds Ethlabs

Bitmine Immersion Technologies (NYSE:BMNR) is approaching inclusion in the Russell 1000 index, which would trigger buying by index-tracking funds once finalized. The company has co founded Ethlabs, a new nonprofit research lab focused on Ethereum, with the goal of supporting institutional use of the network. Bitmine Immersion Technologies operates in the crypto infrastructure space, where institutional interest in digital assets and blockchain tooling continues to evolve. Potential...
NYSE:SGOV
NYSE:SGOVCapital Markets

US Treasury Bond ETFs Back In Focus As Fed Signals Higher Rates

With the US Federal Reserve under Kevin Warsh signaling a more hawkish stance and bond yields reacting, short term US Treasury and government bond ETFs are back in focus for investors weighing risk and income. As markets adjust to the prospect of rate hikes and a smaller, less interventionist central bank, some stocks exposed to this news may appear better positioned than others. This article walks through three positively exposed stocks from the Short-Term US Treasury and Government Bond...
NasdaqCM:ALMU
NasdaqCM:ALMUSemiconductor

Aeluma (ALMU) Pulled Back After Strong Gains, Is The Stock Overvalued?

Aeluma stock: recent moves in context Aeluma (ALMU) shares have seen mixed recent performance, with the stock down 6.4% on the day and 7.5% over the past week, while still up over the past 3 months and year to date. For investors tracking shorter term swings alongside longer term performance, these moves raise questions about how current pricing lines up with Aeluma’s revenue of US$5.196 million and its reported net loss of US$6.004 million. See our latest analysis for Aeluma. At a share...
NYSE:DCH
NYSE:DCHAuto Components

Dauch (DCH) Faces An Undervaluation Debate, Is The Weakness A Buying Opportunity?

Dauch (DCH) has attracted investor attention after a period of share price weakness, with the stock down 8% over the past week and 12% over the past month from its recent close. See our latest analysis for Dauch. Looking beyond this recent weakness, Dauch’s 1-year total shareholder return of 35.89% contrasts with its year to date share price decline of 12.48%. This suggests momentum has cooled following a stronger prior period. If you want to see what else is moving around Dauch’s part of the...
NYSE:UGI
NYSE:UGIGas Utilities

Is UGI (UGI) Undervalued After Its Pennsylvania Rate Case Narrative?

Recent Performance Snapshot for UGI Stock UGI (UGI) has drawn attention after a mixed period for its stock, with the price recently closing at $34.72. Short term returns were positive, although the share price was down over the past month and over the past three months. See our latest analysis for UGI. Looking beyond the latest move, UGI stock shows short term share price momentum that has recently softened, with the year to date share price return down 7.73% while the 3 year total...
NasdaqGS:LITE
NasdaqGS:LITECommunications

Lumentum (LITE) Reveals $400 Million AI Optics Backlog And Data Center Partnerships

Lumentum Holdings (NasdaqGS:LITE) highlighted an AI-focused optics backlog exceeding $400 million at a recent global conference on AI ethics and governance. Leadership outlined how optical circuit switches and co packaged optics are positioned within AI data center infrastructure build outs. The company also discussed AI data center partnerships, emphasizing collaboration with large scale customers and ecosystem players. These comments add fresh detail on Lumentum Holdings' role in AI...
NYSE:FDX
NYSE:FDXLogistics

FedEx (FDX) Is Down 5.5% After Post-Spin Q4 Beat But Softer 2026 EPS Guidance – Has The Bull Case Changed?

FedEx reported its fiscal fourth-quarter and full-year 2026 results, with Q4 revenue rising to US$25,007 million while net income slipped to US$1,598 million, and full-year revenue increasing to US$94,720 million alongside higher annual earnings per share from continuing operations of US$18.55. The company also completed the spin-off of FedEx Freight, raised its annual dividend by 5%, and issued new guidance calling for around 11% revenue growth and diluted EPS of US$16.55 to US$17.75 for...
NasdaqGS:TECH
NasdaqGS:TECHLife Sciences

The Bull Case For Bio-Techne (TECH) Could Change Following Renewed Analyst Support In A Soft Market

On 23 June 2026, TD Cowen analyst Kyle Boucher reiterated a positive view on Bio-Techne, describing it as a premier small to mid-cap option despite ongoing life sciences market softness and recent insider selling. His comments, alongside a broader consensus that still sees moderate upside for the company despite funding and demand headwinds, suggest investors are reassessing how Bio-Techne is valued within a challenged sector. Next, we'll examine how this renewed analyst confidence, despite...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

Is BridgeBio Pharma (BBIO) Undervalued As Rare Disease Launch Hopes Face A Rich P/S?

BridgeBio Pharma stock performance snapshot BridgeBio Pharma (BBIO) trades at $68.63 after a mixed recent performance, with gains over the past week but declines over the month and past 3 months, while its 1 year total return remains positive. Investors watching BridgeBio Pharma may also note annual revenue of $579.96 million alongside a reported net loss of $721.55 million. This highlights an active development pipeline that is not yet translating into positive earnings. See our latest...
NYSE:INFQ
NYSE:INFQTech

Infleqtion (INFQ) Rebounds Sharply, Is The Stock Still Cheap?

Infleqtion stock moves after recent performance swing Infleqtion (INFQ) has drawn attention after a sharp move in its stock, with a 12.3% gain over the past day and a 19.3% rise across the past week prompting closer investor scrutiny. See our latest analysis for Infleqtion. Set against a year-to-date share price return that is down 6.9%, the recent 40.9% 90-day share price return suggests momentum in Infleqtion is building again as investors reassess its quantum computing potential and risk...
NYSE:P
NYSE:PTech

How Investors May Respond To Everpure (P) Expanding Its Data‑Centric AI and Cyber Resilience Platform

At its Pure//Accelerate 2026 event earlier this month, Veeam Software and Everpure expanded their global alliance and unveiled new integrated cyber resilience, DataAI Resilience, and Kubernetes protection capabilities across Everpure’s Enterprise Data Cloud and Portworx stack. Together with Everpure’s new Data Stream and Data Intelligence offerings, these moves push the company further toward a data-centric AI infrastructure role that tightly couples storage, governance, and cyber resilience...
NasdaqCM:MLTX
NasdaqCM:MLTXBiotechs

MoonLake Immunotherapeutics (MLTX) On Phase 3 Data While A 6x P B Valuation Looks Pricey

MoonLake Immunotherapeutics (MLTX) has become a focus for many investors after strong one-year Phase 3 VELA data for sonelokimab in hidradenitis suppurativa and a planned Biologics License Application filing by the end of September. See our latest analysis for MoonLake Immunotherapeutics. That clinical update has come alongside a sharp move in MoonLake Immunotherapeutics’ share price, with a 7-day share price return of 11.80% and a 30-day share price return of 16.66%. However, the 1-year...
NYSE:COR
NYSE:CORHealthcare

Cencora (COR) Launches Nucleus Pilot And Names A New HR Chief

Cencora (NYSE:COR) has launched a multi site pilot of its enhanced Nucleus inventory management solution for specialty physician practices. The company also announced an executive transition in the Chief Human Resources Officer role, bringing in a CHRO from another large corporation. Cencora is drawing attention with these linked operational and leadership moves, as investors weigh what they might mean for the business. The stock recently closed at $281.1, with a value score of 6 and long...
NYSE:XOM
NYSE:XOMOil and Gas

Exxon Mobil (XOM) Wins Supreme Court Ruling Reviving $1 Billion Cuba Claim

U.S. Supreme Court rules 6-3 in favor of Exxon Mobil (NYSE:XOM) in a case involving Cuban state-owned companies. Decision revives Exxon's claim for more than US$1b in damages tied to assets seized in Cuba decades ago. Ruling finds that foreign sovereign immunity does not shield the Cuban entities in this dispute. Outcome may influence how other U.S. companies pursue claims over expropriated property abroad. Exxon Mobil is one of the largest integrated energy companies, with operations that...
NYSE:AMT
NYSE:AMTSpecialized REITs

American Tower (AMT) Is Leaning Harder Into Data Centers As AI Demand Builds

American Tower (NYSE:AMT) is expanding its data center operations as demand tied to AI workloads and multicloud deployments increases. The company is emphasizing its role in digital infrastructure that supports cloud computing alongside its traditional tower leasing business. This shift highlights how AI and cloud trends are influencing American Tower's mix of assets and services. For investors used to thinking of American Tower mainly as a tower landlord, the growing focus on data centers...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Quantum Computing (QUBT) Buys NHanced Semiconductors And Opens Fab 2 For Hardware Push

Quantum Computing Inc. (NasdaqCM:QUBT) has completed its acquisition of NHanced Semiconductors. The deal brings NHanced in as a wholly owned subsidiary of Quantum Computing Inc. The company has launched Fab 2 to support commercial quantum and photonic hardware production. For Quantum Computing Inc., this acquisition is a significant move into chip manufacturing and advanced packaging, which sit at the heart of quantum and photonic hardware. As more computing workloads push into areas like...
NasdaqGS:DFTX
NasdaqGS:DFTXPharmaceuticals

Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120

Definium Therapeutics (NasdaqGS:DFTX) reported positive topline Phase 3 results for DT120 in major depressive disorder. The company completed a US$700 million follow on equity offering to fund regulatory and commercialization plans for DT120. The latest data readout and capital raise were announced together as Definium Therapeutics positions DT120 for potential market entry. Definium Therapeutics focuses on treatments for psychiatric conditions, with DT120 targeting major depressive...